A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Guselkumab (Primary) ; Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms IXORA-R
- Sponsors Eli Lilly and Company
- 02 Dec 2019 Planned End Date changed from 27 Dec 2019 to 9 Jan 2020.
- 16 Oct 2019 Planned End Date changed from 17 Dec 2019 to 27 Dec 2019.
- 03 Oct 2019 Results presented in an Eli Lilly Media Release.